

ASX Release

Release of Shares from Voluntary Escrow

BRISBANE, 3 March 2017: Oventus Medical Ltd (ASX: OVN) is pleased to announce that in accordance with Listing Rule 3.10A Oventus Medical Ltd (“Oventus”) advises that 8,938,975 fully paid ordinary shares will be released from escrow 10 days from the date of this announcement i.e. 17 March 2017.

The escrow period was initiated upon the successful listing of Oventus on 19 July 2017. The released securities were subject to voluntary escrow arrangements.

Oventus will apply for quotation of the 8,938,975 restricted securities within 10 business days after the end of the escrow period as required by Listing Rule 2.8.2.

Following the quotation of the released shares, there will be 43,929,817 quoted securities and 28,070,183 shares remaining in escrow.



STEPHEN DENARO / COMPANY SECRETARY

About Oventus

Oventus is a Brisbane based medical device company that is commercialising a suite of oral appliances for the treatment of sleep apnoea and snoring. Unlike other oral appliances, the Oventus devices have a unique and patented airway within the device that delivers air to the back of the mouth bypassing multiple obstructions from the nose, soft palate and tongue. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, the device actually prevents oral breathing. The O2Vent is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.¹

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, OSA, however many patients have difficulty tolerating CPAP². Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment.³



BETTER SLEEP, BETTER HEALTH
and a **BETTER LIFE**

¹ *Deloitte Access Economics. Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.*

² *Beecroft, et al. Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003*

³ *Sutherland et al. Oral appliance treatment for obstructive sleep apnea: An updated Journal of Clinical Sleep Medicine. February 2014.*